Affinity-Matured scFv Antibodies for TAG-72 Targeting

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current immunotherapy approaches for cancer treatment, such as those targeting TAG-72, suffer from low affinity and specificity, limiting their effectiveness in engaging immune cells to destroy cancer cells.

Innovation Solution

Development of affinity-maturated single chain variable fragment (scFv) antibodies with enhanced binding affinity to TAG-72, combined with bispecific antibodies that engage T-cells to target and destroy malignant cells, utilizing specific CDR sequences in the VH and VL chains and engineered fusion polypeptides to enhance immune cell interaction.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional cancer treatments (surgery, radiation therapy, chemotherapy) are used, then cancer cells can be treated, but they fail to effectively target and eliminate cancer cells expressing TAG-72 antigen

Engineering Contradiction:

Improveeffectiveness of cancer treatmentVSAvoidtargeting capability against TAG-72 positive cancer cells

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent applies affinity maturation to modify the amino acid sequences in the CDR regions of scFv antibodies, changing the binding parameters to achieve higher affinity for TAG-72 antigen. This involves site-directed mutagenesis and selection processes that optimize specific residues in the complementarity determining regions to enhance binding strength and selectivity for TAG-72 positive cancer cells

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent introduces scFv antibodies as intermediary molecules that specifically bind to TAG-72 antigen on cancer cell surfaces. These antibodies serve as mediators between the immune system and cancer cells, enabling targeted recognition and subsequent immune-mediated destruction of TAG-72 positive cancer cells while sparing normal cells

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If existing antibodies are used to target TAG-72, then some binding occurs, but the affinity and specificity are insufficient for effective therapy

Engineering Contradiction:

Improvebinding affinity for TAG-72VSAvoidcomplexity of antibody optimization process

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The patent performs preliminary affinity maturation through in silico modeling and in vitro selection to pre-optimize scFv antibodies before clinical use. This preliminary optimization of CDR sequences ensures high binding affinity is achieved during the development phase, reducing the need for complex optimization during manufacturing and clinical application

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent replaces traditional mechanical or chemical methods of antibody production with molecular biology techniques including site-directed mutagenesis, phage display selection, and recombinant DNA technology. This substitution enables precise engineering of CDR regions to achieve desired binding characteristics while streamlining the manufacturing process

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Data Source

PatentUS12624122B2Affinity maturated TAG72 specific single chain antibodies

Publication Date: 2026.05.12 H LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE INC

AI summary

Disclosed are compositions and methods for targeted treatment of TAG-72-expressing cancers. In particular, affinity maturated single chain variable fragment (scFv) antibodies that bind TAG-72 on cancer cells are disclosed.